Niaprazine: Difference between revisions
No edit summary |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 24: | Line 24: | ||
| routes_of_administration = Oral | | routes_of_administration = Oral | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
| Line 35: | Line 35: | ||
{{Hypnotics and sedatives}} | {{Hypnotics and sedatives}} | ||
{{antihistamines}} | {{antihistamines}} | ||
[[Category:Piperazines]] | [[Category:Piperazines]] | ||
Revision as of 14:18, 20 August 2012
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 4.53 +- 0.86 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H25FN4O |
| Molar mass | 356.437 |
|
WikiDoc Resources for Niaprazine |
|
Articles |
|---|
|
Most recent articles on Niaprazine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Niaprazine at Clinical Trials.gov Clinical Trials on Niaprazine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Niaprazine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Niaprazine Discussion groups on Niaprazine Patient Handouts on Niaprazine Directions to Hospitals Treating Niaprazine Risk calculators and risk factors for Niaprazine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Niaprazine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Niaprazine (Nopron) is a piperazine derivative drug which acts as a sedating antihistamine. It was invented in the 1970s [1], and is used in France, Italy and other european countries. It is mainly prescribed for its relatively strong sedative effects rather than as an antihistamine, and is used mainly for treating autism [2] and insomnia [3] in children and adolescents. Common side effects are: sedation during the day (especially during the first few days of treatment) and dizziness.
References
- ↑ Duchene-Marullaz P, Rispat G, Perriere JP, Hache J, Labrid C. Some pharmacodynamical properties of niaprazine, a new antihistaminic agent. (French) Therapie. 1971 Nov-Dec;26(6):1203-9.
- ↑ Rossi PG, Posar A, Parmeggiani A, Pipitone E, D'Agata M. Niaprazine in the treatment of autistic disorder. Journal of Child Neurology. 1999 Aug;14(8):547-50.
- ↑ Younus M, Labellarte MJ. Insomnia in children: when are hypnotics indicated? Paediatric Drugs. 2002;4(6):391-403.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Piperazines